Details of most recent positions

Biota Holdings – Expert Consultant – Feb 04 to Aug 08

| Expert consultant to lawyers engaged in commercial litigation

| Explained complex scientific issues to the legal team

| Assisted in the preparation of questions for expert witnesses

| Prepared technical reports, chronologies and literature reviews for the case


Cryptopharma – Chairman – Dec 03 to Apr 08

| Chaired Board meetings as an independent, non-executive Director

| Participated in Scientific Advisory Board meetings during the initial years of the Company


Boron Molecular - CEO & Managing Director - Mar 02 to May 03

| Overall responsibility for the management of the Company

| Stabilized the business & recruited management team

| Raised $1.9M through a private placement

| Wrote new business plan for redirection of corporate strategy

| Prepared prospectus for a public offering

| Grew revenues in 1st three quarters of 2002/3 by >100% compared with same period in 2001/2

| Attained near breakeven

| Established systems and quality control procedures


Biota Holdings – Director R&D/General Manager - Sep 93 to Feb 02

| Responsible for all research and development activities of the Company

| Initiated and completed development of the flu diagnostic, FLU OIA®, for international marketing

| Built R&D team as inaugural R&D Director

| Established laboratory facilities

| Managed R&D relationship with GSK on Relenza®

| Diversified Biota’s R&D portfolio


Parke-Davis (Ann Arbor, MI, USA) – Director, Clinical Pharmacology – Sep 90 to Sep 93

| Managed transition of new pharmaceuticals for CNS diseases from pre-clinical to Phase I and Phase IIA clinical studies

| Managed staff involved in Phase I and IIA CNS studies

| Prepared clinical pharmacology reports for IND and NDA applications

| Reviewed pre-clinical data for suitability for IND applications and Phase I studies in CNS

| Attended all research and team meetings in the CNS preclinical and clinical area